HCMV infection and antiviral treatment according to D/R serostatus
. | No. of patients (%) in the randomization arm . | . | . | . | . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| . | IEmRNA . | . | . | Antigenemia . | . | . | |||||
| . | Total . | HCMV infected . | Treated . | Total . | HCMV infected . | Treated . | |||||
| HCMV serostatus . | n = 41 . | n = 33 . | n = 27 . | n = 39 . | n = 20 . | n = 14 . | |||||
| D+/R+ | 20 | 15 (75.0) | 11 (55.0) | 22 | 15 (68.2) | 13 (59.1) | |||||
| D-/R+ | 17 | 14 (82.4) | 14 (82.4) | 11 | 4 (36.4) | 4 (36.4) | |||||
| D+/R- | 4 | 4 (100) | 2 (50.0) | 6 | 1 (16.7) | 0 | |||||
| R- vs R+, P* | NA | NS | NS | NA | .092 | .027 | |||||
| D- vs D+, P* | NA | NS | .096 | NA | NS | NS | |||||
. | No. of patients (%) in the randomization arm . | . | . | . | . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| . | IEmRNA . | . | . | Antigenemia . | . | . | |||||
| . | Total . | HCMV infected . | Treated . | Total . | HCMV infected . | Treated . | |||||
| HCMV serostatus . | n = 41 . | n = 33 . | n = 27 . | n = 39 . | n = 20 . | n = 14 . | |||||
| D+/R+ | 20 | 15 (75.0) | 11 (55.0) | 22 | 15 (68.2) | 13 (59.1) | |||||
| D-/R+ | 17 | 14 (82.4) | 14 (82.4) | 11 | 4 (36.4) | 4 (36.4) | |||||
| D+/R- | 4 | 4 (100) | 2 (50.0) | 6 | 1 (16.7) | 0 | |||||
| R- vs R+, P* | NA | NS | NS | NA | .092 | .027 | |||||
| D- vs D+, P* | NA | NS | .096 | NA | NS | NS | |||||
NA indicates not applicable; NS, not significant.
Fisher exact test.